So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

生物技术公司Viking Therapeutics(VKTX.US)公布，其口服减肥药物的一期试验结果好於预期，股价周一盘前曾涨逾5%。 公司指，针对 ...

在没有上市药物的生物科技公司中，Viking当前的资产负债情况非常优越。从投资的角度分析，该股未来增发股票导致股权被稀释的风险很低，承受临床项目失败的抗风险能力很强。即使试验数据不佳可能导致股价回落，但不会对财务造成重大的冲击。

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

The pharmaceutical company Viking has recently become one of the most volatile stocks on Wall Street due to the announcement ...

近两年随着数据中心快速发展推动电力需求飙升，全球电力变压器市场供应紧张的问题日益突出，供货周期延长至3到4年。变压器对于改变电压至关重要，可使电力高效地从发电厂流向最终用户。挪威咨询机构睿咨得能源预测，到2030年，全球变压器市场规模有望从目前的480亿美元大幅提升至670亿美元。该机构分析师直言，电力变压器是目前供应不足问题最突出的关键电网设备，由于增产困难，该产业正面临前所未有的压力，预计变压 ...

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...

Losing more than 8% of weight in less than a month. This is the promise of a pill under experimentation in the laboratories ...

Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

AstraZeneca’s new obesity pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.

While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...